UroGen presented sub-analysis data from the real-world patient cohort review of Jelmyto (mitomycin) for pyelocalyceal solution at AUA 2024
The low-grade Ta UTUC patients responding completely to induction therapy (n=53) had RFS rate of 86% at 24mos., irrespective of initial disease characteristics or usage for chemoablation vs post-endoscopic ablation. Those who received maintenance therapy (30% complete responders) had an RFS of 100% vs 61% for those who did not at 24mos.
Investigators are currently recruiting patients in the prospective & retrospective uTRACT Registry assessing Jelmyto’s potential for treating UTUC to record data in a large-scale, standardized manner for reporting patient outcomes
Ref: UroGen Pharma | Image: UroGen Pharma
Related News:- UroGen Presents P-III (OLYMPUS) Trial Results of Jelmyto (mitomycin) for the Treatment of Low-Grade Upper Tract Urothelial Cancer at SUO 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
